Roselle (Hibiscus sabdariffa L.) extract as an adjunct to valsartan in patients with mild chronic kidney disease: A double-blind randomized controlled clinical trial

سال انتشار: 1403
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 147

فایل این مقاله در 15 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_AJP-14-4_008

تاریخ نمایه سازی: 23 خرداد 1403

چکیده مقاله:

Objective: The objective of this study was to evaluate theeffectiveness of Hibiscus sabdariffa L. extract (HS) as an adjunctto valsartan in the treatment of high blood pressure in patients withmild chronic kidney disease (CKD).Materials and Methods: This trial was conducted in Gorgan,Iran. Seventy-two participants with CKD and high blood pressurewere randomly assigned to either the HS group, receiving a ۳۵۰mg pill every ۱۲ hr for ۹۰ days along with ۴۰ mg of valsartanevery ۱۲ hr, or the control group (۴۰ mg valsartan + ۱۲.۵ mghydrochlorothiazide). The primary objective was to assess theimprovement of hypertension, while secondary objectives includedthe evaluation of proteinuria, albuminuria, kidney function, lipidprofile, and electrolyte levels. Molecular docking analysis wasperformed to examine the mechanisms of action of the isolatedcomponents of HS.Results: Out of ۸۰ initial participants, ۷۲ were included in theanalysis. Both groups showed a significant reduction in bloodpressure (p<۰.۰۰۱). The HS group demonstrated a statisticallysignificant decrease in lipid profile (p<۰.۰۰۱). There were nostatistically significant differences between the groups regardingthe reduction of renal markers. Molecular docking analysisrevealed that the compounds present in HS, particularly itsanthocyanins and flavonoids, exhibited greater angiotensinconverting enzyme (ACE) inhibitory potential thanhydrochlorothiazide in both domains. Moreover, the compoundsmet the criteria for drug likeness and Lipinski rules.Conclusion: Adjunctive therapy with HS showed promisingresults in reducing hypertension and improving lipid profile inpatients with CKD.

نویسندگان

Behdad Dehkhoda

Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Ayesheh Enayati

Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Hassan Mirzaei

Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Somayeh Ghorbani

Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Mohammad Hadi Soleimani

Giah Essence Phytopharm-Dr. Soleimani Co.

Saeid Amirkhanlou

Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran

Amirhossein Sahebkar

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran